Affordable Access

Access to the full text

AVE0991, a nonpeptide angiotensin-(1–7) mimic, inhibits angiotensin II–induced abdominal aortic aneurysm formation in apolipoprotein E knockout mice

Authors
  • Ma, Hui1
  • Wang, Yu-Lin1
  • Hei, Nai-Hao1
  • Li, Jun-Long1
  • Cao, Xin-Ran1
  • Dong, Bo1
  • Yan, Wen-jiang2
  • 1 Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China , Jinan (China)
  • 2 Qilu Hospital of Shandong University, Jinan, Shandong, China , Jinan (China)
Type
Published Article
Journal
Journal of Molecular Medicine
Publisher
Springer-Verlag
Publication Date
Feb 14, 2020
Volume
98
Issue
4
Pages
541–551
Identifiers
DOI: 10.1007/s00109-020-01880-4
Source
Springer Nature
Keywords
License
Yellow

Abstract

AbstractAVE0991, a nonpeptide angiotensin-(1–7) mimic, has similar protective effects for cardiovascular system to Ang-(1–7). In this article, we aimed to explore the effects of AVE0991 and Ang-(1–7) on abdominal aortic aneurysm (AAA) induced by Ang II in apolipoprotein E knockout mice. The mice AAA model was established by Ang II infusion, and then mice received different treatment with saline, Ang II (1.44 mg/kg/day), different dose AVE0991 (0.58 or 1.16 μmol/kg/day), or Ang-(1–7) (400 ng/kg/min). The incidence of AAA was 76%, 48%, 28%, and 24% in the vehicle, the low-dose AVE0991, high-dose AVE0991, and the Ang-(1–7) group, respectively. In comparison with control group, AVE0991 and Ang-(1–7) treatment significantly increased smooth muscle cells and decreased macrophage accumulation, the expression levels of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor α (TNF-α), and the expression and activity of metalloproteinases 2 and 9 in mice AAA model or in human smooth muscle cells (hVSMCs). The therapeutic effects may be contributed to reduction of oxidative stress and downregulation of P38 and ERK1/2 signal pathways via Mas receptor activation, whereas the positive impacts were reversed by co-administration with the Mas antagonist A779 (400 ng/kg/min) and AVE0991 in Ang II–infused mice or in hVSMCs. Therefore, AVE0991 and Ang-(1–7) might be novel and promising interventions in the prevention and treatment of AAA.Key messages• AVE0991 dose-dependently inhibited Ang II–induced AAA formation in Apoe−/− mice.• Ang-(1–7) played the same protective role as high-dose AVE0991.• Inhibition of Mas receptor with A779 could reverse the protective effect of AVE0991.• The therapeutic effects may be contributed to reduction of oxidative stress and downregulation of P38 and ERK1/2 signal pathways via Mas receptor activation.

Report this publication

Statistics

Seen <100 times